It is hypothesized that L-arginine (ARG) can improve etoposide (VP-16) water solubility while preserving its anticancer activity. Factorial design is used to identify conditions for optimum drug aqueous solubility after freeze-drying. The physicochemical properties of the optimized formulation is further analyzed by X-ray powder diffraction, scanning electron microscopy, proton nuclear magnetic resonance, and fourier transform infrared spectroscopy. Drug stability in formulation is analyzed using mass spectrometry based fragmentation analysis. Liquid chromatography tandem mass spectrometry and cell viability assay on Michigan Cancer Foundation-7 (MCF-7) cell line are performed to assess the drug cellular uptake and the anticancer activity, respectively. At the VP-16: ARG ratio of 4:10 (w/w), the drug apparent solubility increased significantly (∼65-folds) with a 3.5-fold improvement in the drug dissolution rate. The interaction between VP-16 and ARG transforms the drug from crystalline to amorphous solid state. VP-16-ARG complex in lower native drug concentration range (50–300 μM) has lower anticancer activity compared with native VP-16, due to reduced intracellular transport of the more hydrophilic complex as indicated by the cell viability assay and confirmed by cell uptake study. However, at higher drug concentrations (500 μM) the complex's higher anticancer activity is ascribed to the synergistic effect between ARG and VP-16. These data suggest that an optimal ARG concentration can have positive effects with potential benefits for chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
MoffatJG, RudolphJ, BaileyD: Phenotypic screening in cancer drug discovery—past, present and future. Nat Rev Drug Discov, 2014; 13:588.
2.
WuG, ZhaoT, KangD, et al.: Overview of recent strategic advances in medicinal chemistry. J Med Chem, 2019; 62:9375–9414.
3.
Merisko-LiversidgeE, SarpotdarP, BrunoJ, et al.: Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res, 1996; 13:272–278.
4.
KalepuS, NekkantiV: Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B, 2015; 5:442–453.
5.
KaragianniA, KachrimanisK, NikolakakisI: Co-amorphous solid dispersions for solubility and absorption improvement of drugs: composition, preparation, characterization and formulations for oral delivery. Pharmaceutics, 2018; 10:98.
6.
EsparzaK, OnyukselH: Development of co-solvent freeze-drying method for the encapsulation of water-insoluble thiostrepton in sterically stabilized micelles. Int J Pharm, 2019; 556:21–29.
7.
GirekM, KłosińskiK, GrobelskiB, et al.: Novel tetrahydroacridine derivatives with iodobenzoic moieties induce G0/G1 cell cycle arrest and apoptosis in A549 non-small lung cancer and HT-29 colorectal cancer cells. Mol Cell Biochem, 2019; 460:123–150.
8.
LavoieJ-M, KollmannsbergerCK: Current management of disseminated germ cell tumors. Urol Clin North Am, 2019; 46:377–388.
9.
van MaanenJMS, RetèlJ, de VriesJ, PinedoHM: Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst, 1988; 80:1526–1533.
10.
CanelaA, MamanY, HuangSN, et al.: Topoisomerase II-induced chromosome breakage and translocation is determined by chromosome architecture and transcriptional activity. Mol Cell, 2019; 75:252–266.e8.
11.
AthawaleRB, JainDS, SinghKK, GudeRP: Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung. Biomed Pharmacother, 2014; 68:231–240.
12.
SiderovJ, PrasadP, De BoerR, DesaiJ: Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer, 2002; 86:12–13.
13.
SerajuddinATM: Salt formation to improve drug solubility. Adv Drug Deliv Rev, 2007; 59:603–616.
14.
KastenG, LoboL, DengaleS, GrohganzH, RadesT, LöbmannK: In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine. Eur J Pharm Biopharm, 2018; 132:192–199.
15.
ChiengN, AaltonenJ, SavilleD, RadesT: Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. Eur J Pharm Biopharm, 2009; 71:47–54.
YamamuraS, GotohH, SakamotoY, MomoseY: Physicochemical properties of amorphous salt of cimetidine and diflunisal system. Int J Pharm, 2002; 241:213–221.
18.
ArakawaT, KitaY, KoyamaAH: Solubility enhancement of gluten and organic compounds by arginine. Int J Pharm, 2008; 355:220–223.
19.
LöbmannK, GrohganzH, LaitinenR, StrachanC, RadesT: Amino acids as co-amorphous stabilizers for poorly water soluble drugs—Part 1: preparation, stability and dissolution enhancement. Eur J Pharm Biopharm, 2013; 85(3, Part B):873–881.
20.
OjarintaR, LerminiauxL, LaitinenR: Spray drying of poorly soluble drugs from aqueous arginine solution. Int J Pharm, 2017; 532:289–298.
21.
AffandiMMRMM, TripathyM, MajeedABA: Arginine complexes with simvastatin: apparent solubility, in vitro dissolution and solid state characterization. Curr Drug Deliv, 2018; 15:77–86.
22.
JahaniM, AzadbakhtM, NorooznezhadF, MansouriK: l-arginine alters the effect of 5-fluorouracil on breast cancer cells in favor of apoptosis. Biomed Pharmacother, 2017; 88:114–123.
23.
Loignon-HouleF, BergeronM, PepinCM, CharleboisSA, LecomteR: Simulation of scintillation light output in LYSO scintillators through a full factorial design. Phys Med Biol, 2017; 62:669–683.
24.
Reyes-RiveraJ, TerrazasT: Lignin analysis by HPLC and FTIR. In: Xylem: Methods and Protocols. de Lucas M, Etchhells JP (eds.), pp. 193–211. Springer New York, New York, NY, 2017.
25.
MandalA, PatelP, PalD, MitraAK: Multi-layered nanomicelles as self-assembled nanocarrier systems for ocular peptide delivery. AAPS PharmSciTech, 2019; 20:66.
RazboršekMI, IvanovićM: Stability studies and determination of carnosic acid and its oxidative degradation products by gas chromatography–mass spectrometry. Int J Mass Spectrom, 2016; 407:29–39.
28.
SherjeAP, DesaiKJ: Spectrophotometric determination of poorly water soluble drug rosiglitazone using hydrotropic solubilization technique. Indian J Pharm Sci, 2011; 73:579–582.
29.
NgoAN, ThomasD, MurowchickJ, AyonNJ, JaiswalA, YouanB-BC: Engineering fast dissolving sodium acetate mediated crystalline solid dispersion of docetaxel. Int J Pharm, 2018; 545:329–341.
30.
KulkarniYM, YakisichJS, AzadN, et al.: Anti-tumorigenic effects of a novel digitoxin derivative on both estrogen receptor–positive and triple-negative breast cancer cells. Tumour Biol, 2017; 39:1010428317705331.
31.
NaguibYW, RodriguezBL, LiX, HurstingSD, WilliamsRO, CuiZ: Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm, 2014; 11:1239–1249.
32.
GargNK, SinghB, KushwahV, et al.: The ligand (s) anchored lipobrid nanoconstruct mediated delivery of methotrexate: an effective approach in breast cancer therapeutics. Nanomedicine, 2016; 12:2043–2060.
33.
NikkhahM, StroblJS, SchmelzEM, RobertsPC, ZhouH, AgahM: MCF10A and MDA-MB-231 human breast basal epithelial cell co-culture in silicon micro-arrays. Biomaterials, 2011; 32:7625–7632.
34.
CoulibalyFS, EzoulinMJM, PurohitSS, AyonNJ, OylerNA, YouanBC: Layer-by-layer engineered microbicide drug delivery system targeting HIV-1 gp120: physicochemical and biological properties. Mol Pharm, 2017; 14:3512–3527.
35.
AyonNJ, SharmaAD, GutheilWG: LC-MS/MS-based separation and quantification of Marfey's reagent derivatized proteinogenic amino acid dl-stereoisomers. J Am Soc Mass Spectrom, 2019; 30:448–458.
36.
EinfaltT, PlaninšekO, HrovatK: Methods of amorphization and investigation of the amorphous state. Acta Pharm, 2013; 63:305–334.
37.
MahadeviAS, SastryGN: Cation− π interaction: its role and relevance in chemistry, biology, and material science. Chem Rev, 2013; 113:2100–2138.
38.
QiX, ZhangJ, WangW, CaoD: Solubility and stability of indomethacin in arginine-assisted solubilization system. Pharm Dev Technol, 2013; 18:852–855.
39.
SolanoAGR, de Fátima PereiraA, PintoFCH, et al.: Development and evaluation of sustained-release etoposide-loaded poly(ɛ-caprolactone) implants. AAPS Pharm Sci Tech, 2013; 14:890–900.
40.
ForbesMW, BushMF, PolferNC, et al.: Infrared spectroscopy of arginine cation complexes: direct observation of gas-phase zwitterions. J Phys Chem A, 2007; 111:11759–11770.
41.
YoonKJ, QiJ, RemackJS, et al.: Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. Mol Cancer Ther, 2006; 5:1577.
42.
NoZ, LeeS-G: Complete 1H and 13C assignments of some epipodophyllotoxin derivatives. Magn Reson Chem, 2003; 41:283–286.
CourvoisierE, WilliamsPA, LimGK, HughesCE, HarrisKDM: The crystal structure of l-arginine. Chem Commun, 2012; 48:2761–2763.
45.
AddalaS, BouhdjerL, ChalaA, et al.: Structural and optical properties of a NaCl single crystal doped with CuO nanocrystals. Chin Phys B, 2013; 22:098103.
46.
CampbellBI, La BountyPM, RobertsM: The ergogenic potential of arginine. J Int Soc Sports Nutr, 2004; 1:35–38.
47.
ArturssonP, PalmK, LuthmanK: Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev, 1996; 22:67–84.
48.
ChaYJ, KimE-S, KooJS: Amino acid transporters and glutamine metabolism in breast cancer. Int J Mol Sci, 2018; 19:907.
49.
WuG, DavisPK, FlynnNE, KnabeDA, DavidsonJT: Endogenous synthesis of arginine plays an important role in maintaining arginine homeostasis in postweaning growing pigs. J Nutr, 1997; 127:2342–2349.
50.
ZhangR, QinX, KongF, ChenP, PanG: Improving cellular uptake of therapeutic entities through interaction with components of cell membrane. Drug Deliv, 2019; 26:328–342.
